3 completed, 1 recruiting, 1 terminated. 5 Phase 2, 2 Phase 1.
| Phase | Trials | Status |
|---|---|---|
| Phase 2 | 5 | Completed 3, Recruiting 1, Terminated 1 |
| Phase 1 | 2 | Recruiting 1, Terminated 1 |
Follow Primary Open-Angle Glaucoma (POAG): new trials by email Literature Review of Primary Open-Angle Glaucoma (POAG) trials Research Report on Primary Open-Angle Glaucoma (POAG)
Tick up to 5 trials to compare them side by side (eligibility, arms, endpoints, adverse events) in a Literature Matrix.
| Trial | Phase | Status | Sponsor | Enrollment | Start | Updated |
|---|---|---|---|---|---|---|
| GVB-2001 Gene Therapy Via Intracameral Injection for the Treatment of Primary Open Angle Glaucoma GVB-2001-high dose, GVB-2001-low dose - Primary Open-Angle Glaucoma (POAG) | Phase 1 / Phase 2 | Recruiting | IVIEW Therapeutics Inc. | 6 | 2025-11-19 | 2026-05-04 |
| Efficacy and Safety of Different Dosages of Mexidol® in Patients With Primary Open-angle Glaucoma (POAG) Mexidol, Placebo - Primary Open-Angle Glaucoma (POAG) | Phase 2 | Completed | Pharmasoft | 102 | 2021-11-15 | 2025-12-12 |
| Study of Fixed-Dose Combinations of Trabodenoson and Latanoprost in Adults With OHT or POAG trabodenoson 6.0% / latanoprost 0.005% QD, trabodenoson 3.0% / latanoprost 0.005% QD, trabodenoson 6.0% / latanoprost 0.0025% QD - Primary Open-Angle Glaucoma (POAG), Ocular Hypertension (OHT) | Phase 2 | Completed | Inotek Pharmaceuticals Corporation | 201 | 2016-08-19 | 2018-02-15 |
| Safety and Efficacy of Deep Wave Trabeculoplasty (DWT) in Primary Open Angle Glaucoma and Ocular Hypertension DWT device dose A, Ellex Tango SLT machine, DWT device dose B - Primary Open-angle Glaucoma (POAG), Ocular Hypertension (OHT) | Phase 1 / Phase 2 | Terminated | OcuTherix, Inc. | 35 | 2013-11-01 | 2017-04-04 |
| A Phase II Study to Evaluate the Additivity of Trabodenoson to Latanoprost in Adults With Ocular Hypertension or Primary Open-Angle Glaucoma Trabodenoson, Latanoprost, Timolol - Primary Open-Angle Glaucoma (POAG), Ocular Hypertension (OHT) | Phase 2 | Completed | Inotek Pharmaceuticals Corporation | 101 | 2013-08-01 | 2017-12-02 |
Glaucoma (5) · Glaucoma, Open-Angle (5) · Ocular Hypertension (3) · Mitochondrial Diseases (1) · Night Blindness, Congenital Stationary, Autosomal Dominant 1 (1)
Eye Diseases (5) · Ocular Hypertension (2) · Metabolic Diseases (1) · Nutritional and Metabolic Diseases (1)
Latanoprost (2) · trabodenoson (2) · INO-8875 (1) · Timolol (1) · emoxypine succinate (1) · ethylmethylhydroxypyridine succinate (1)
Inotek Pharmaceuticals Corporation (2) · IVIEW Therapeutics Inc. (1) · OcuTherix, Inc. (1) · Pharmasoft (1)
United States (2) · China (1) · Philippines (1) · Russia (1)
Cadmus C Rich, MD,MBA,CPE (1) · Edgar U. Leuenberger, MD (1) · Harvey Siy Uy, MD (1) · Maria I Yap-Veloso, MD (1) · Peirong Lu, MD (1)